NCT04083378 · OUTCOME

Cumulative Incidence of 2-year Local Tumor Progression

Software-Aided Imaging (Morfeus) for Confirming Tumor Coverage With Ablation in Patients With Liver Tumors, the COVER-ALL Study · Source last updated 2026-03-23

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: percentage of participants
Interval / dispersion: Not reported
Time frame: Time to local tumor progression (LTP) was measured from ablation to earliest LTP or death (competing event). Follow-up imaging continued up to 24 months.

What was measured

A competing risk analysis was conducted to estimate the 2-year cumulative incidence of local tumor progression. Progression followed ablation reporting standards and RECIST v1.1 (mRECIST for HCC).

Analysis population: The 2-year secondary endpoints were evaluated for the randomized group

Groups in this outcome

Experimental

Clinical impact of Morfeus software usage on patients undergoing percutaneous thermal ablation of liver tumors

Control

Morfeus software was not used during percutaneous thermal ablation of liver tumors

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Experimental	74
Control	26

Reported measurements

Source class 1

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Experimental	6	Not reported	Not reported	Not reported	Not reported
Control	17.9	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
6
group Id
OG001
value
17.9

denoms

counts
group Id
OG000
value
74
group Id
OG001
value
26
units
Participants

description

A competing risk analysis was conducted to estimate the 2-year cumulative incidence of local tumor progression. Progression followed ablation reporting standards and RECIST v1.1 (mRECIST for HCC).

groups

description
Clinical impact of Morfeus software usage on patients undergoing percutaneous thermal ablation of liver tumors
id
OG000
title
Experimental
description
Morfeus software was not used during percutaneous thermal ablation of liver tumors
id
OG001
title
Control

param Type

NUMBER

population Description

The 2-year secondary endpoints were evaluated for the randomized group

reporting Status

POSTED

time Frame

Time to local tumor progression (LTP) was measured from ablation to earliest LTP or death (competing event). Follow-up imaging continued up to 24 months.

title

Cumulative Incidence of 2-year Local Tumor Progression

type

SECONDARY

unit Of Measure

percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice